Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs

Park, Joon Ho; Jiang, Yao; Zhou, Jiarong; Gong, Hua; Mohapatra, Animesh; Heo, Jiyoung; Gao, Weiwei; Fang, Ronnie H.; Zhang, Liangfang

doi:10.1126/sciadv.abf7820

Cited by 127 publications

(133 citation statements)

References 53 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…Alternatively, targeted EC therapies, as discussed below, may be considered for the resolution of vascular inflammation at the site of the activated endothelium in atherosclerosis. Prospective agents for targeted resolution include ICAM-1- or VCAM-1-targeted nanocarriers, which have previously been employed to limit neurovascular ( Lutton et al, 2017 ; Marcos-Contreras et al, 2020 ) and pulmonary inflammation ( Li S. et al, 2018 ; Park et al, 2021 ) in experimental models of disease.…”

Section: The Vascular Endothelium As An Emerging Therapeutic Target For Atherosclerosismentioning

confidence: 99%

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment

2021

View full text Add to dashboard Cite

Atherosclerosis, the chronic accumulation of cholesterol-rich plaque within arteries, is associated with a broad spectrum of cardiovascular diseases including myocardial infarction, aortic aneurysm, peripheral vascular disease, and stroke. Atherosclerotic cardiovascular disease remains a leading cause of mortality in high-income countries and recent years have witnessed a notable increase in prevalence within low- and middle-income regions of the world. Considering this prominent and evolving global burden, there is a need to identify the cellular mechanisms that underlie the pathogenesis of atherosclerosis to discover novel therapeutic targets for preventing or mitigating its clinical sequelae. Despite decades of research, we still do not fully understand the complex cell-cell interactions that drive atherosclerosis, but new investigative approaches are rapidly shedding light on these essential mechanisms. The vascular endothelium resides at the interface of systemic circulation and the underlying vessel wall and plays an essential role in governing pathophysiological processes during atherogenesis. In this review, we present emerging evidence that implicates the activated endothelium as a driver of atherosclerosis by directing site-specificity of plaque formation and by promoting plaque development through intracellular processes, which regulate endothelial cell proliferation and turnover, metabolism, permeability, and plasticity. Moreover, we highlight novel mechanisms of intercellular communication by which endothelial cells modulate the activity of key vascular cell populations involved in atherogenesis, and discuss how endothelial cells contribute to resolution biology – a process that is dysregulated in advanced plaques. Finally, we describe important future directions for preclinical atherosclerosis research, including epigenetic and targeted therapies, to limit the progression of atherosclerosis in at-risk or affected patients.

show abstract

Section: The Vascular Endothelium As An Emerging Therapeutic Target For Atherosclerosismentioning

confidence: 99%

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment

2021

View full text Add to dashboard Cite

show abstract

“…Recently, it has been reported that the NSC can be better used to promote damage repair by engulfing anti-inflammatory nanoparticles (104). Exploring the effect of exogenous NSC on SCI, the way of combining new materials and targeted delivery of NSC may become a research hotspot in the future (105).…”

Section: Stem Cell Transplantationmentioning

confidence: 99%

Current Knowledge of Microglia in Traumatic Spinal Cord Injury

Wang

Ding

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

Microglia are the resident immune cells in the central nervous system (CNS). After traumatic spinal cord injury (SCI), microglia undergo activation, proliferation, and changes in gene and protein expression and morphology, with detrimental and beneficial effects. Activated microglia cause secondary neuronal injury via the production of proinflammatory cytokines, reactive oxygen species, and proteases. However, activated microglia also promote neuronal repair through the secretion of anti-inflammatory growth factors and cytokines. Proinflammatory cytokines increase endothelial permeability, promote A1 astrocyte activation and axonal demyelination, and reduce neural stem/progenitor cells (NSPCs), leading to the exacerbation of neuronal injury. In contrast, anti-inflammatory factors facilitate angiogenesis, reduce reactive astrocytes, and promote axonal remyelination and the propagation of NSPCs, contributing to tissue repair and locomotor recovery. Due to its limited regenerative capacity, the CNS requires beneficial microglia for continuous protection against injury. Understanding and regulating microglial activation status are beneficial to reducing detrimental effects and promoting repair behaviors and to obtain more information on efficient therapies for traumatic SCI. This review discusses microglial activation and the differences between microglia and similar immune cells, microglial interactions with other cells in the spinal cord, and the progress in the development of therapies targeting microglia in SCI.

show abstract

“…(B) Schematic illustration of genetically engineered cell membrane–coated nanoparticles for targeted DEX to inflamed lungs. (Reproduced with permission from Park et al (2021) ).…”

Section: Engineered Cell Membrane-encapsulated Nanoparticlesmentioning

confidence: 99%

Engineered Cell Membrane-Derived Nanocarriers: The Enhanced Delivery System for Therapeutic Applications

Xue

Yin

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

There has been a rapid development of biomimetic platforms using cell membranes as nanocarriers to camouflage nanoparticles for enhancing bio-interfacial capabilities. Various sources of cell membranes have been explored for natural functions such as circulation and targeting effect. Biomedical applications of cell membranes-based delivery systems are expanding from cancer to multiple diseases. However, the natural properties of cell membranes are still far from achieving desired functions and effects as a nanocarrier platform for various diseases. To obtain multi-functionality and multitasking in complex biological systems, various functionalized modifications of cell membranes are being developed based on physical, chemical, and biological methods. Notably, many research opportunities have been initiated at the interface of multi-technologies and cell membranes, opening a promising frontier in therapeutic applications. Herein, the current exploration of natural cell membrane functionality, the design principles for engineered cell membrane-based delivery systems, and the disease applications are reviewed, with a special focus on the emerging strategies in engineering approaches.

show abstract

Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs

Cited by 127 publications

References 53 publications

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment

Current Knowledge of Microglia in Traumatic Spinal Cord Injury

Engineered Cell Membrane-Derived Nanocarriers: The Enhanced Delivery System for Therapeutic Applications

Contact Info

Product

Resources

About